Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Comparative Effectiveness of the mRNA-1273 Vaccine vs. BNT162b2 Vaccine Among Immunocompromised Adults in the United States

NCT05366322 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05366322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Comparative Effectiveness of the mRNA-1273 Vaccine vs. BNT162b2 Vaccine Among Immunocompromised Adults in the United States
Lead sponsor
ModernaTX, Inc.
Phase
Observational
Overall status
Completed
Start date
September 10, 2021
Completion date
March 21, 2022
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2